A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir DOI Creative Commons
Luke B. Snell, Aimée McGreal-Bellone, Clemency Nye

и другие.

Open Forum Infectious Diseases, Год журнала: 2023, Номер 11(1)

Опубликована: Дек. 7, 2023

The optimum treatment for persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where SARS-CoV-2 was successfully treated prolonged courses (median, 10 days [range, 10-18 days]) of nirmatrelvir/ritonavir (Paxlovid). Most (9/11) had hematological malignancy and (10/11) received CD20-depleting therapy. median duration 103 (interquartile range, 85-138 days). majority were hospitalized, 7 (7/11) severe/critical disease. All survived 9 demonstrated viral clearance, almost half (4/9) whom as monotherapy. This series suggests that has a role treating infection.

Язык: Английский

Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management DOI
Suzy Meijer, Yael Paran,

Ana Belkin

и другие.

Clinical Microbiology and Infection, Год журнала: 2024, Номер 30(8), С. 1012 - 1017

Опубликована: Апрель 18, 2024

Язык: Английский

Процитировано

11
Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study DOI Creative Commons
Remigius Gröning,

J Walde,

Clas Ahlm

и другие.

International Journal of Infectious Diseases, Год журнала: 2024, Номер 144, С. 107046 - 107046

Опубликована: Апрель 12, 2024

ObjectivesTo investigate the effectiveness of intravenous immunoglobulin (IVIG) as treatment for COVID-19 in immunocompromised patients.MethodsThis retrospective study investigated outcomes immunocompromised, vaccine non-responsive, patients that between September 2022 and April 2023 received IVIG region Västerbotten, Sweden. We analyzed clinical data, viral load, anti-SARS-CoV-2 IgG binding neutralization levels patient serum samples production batches. Primary secondary were cure clearance, respectively.ResultsSixteen analyzed. After a median duration four weeks, 60g infusion increased SARS-CoV-2 neutralizing antibody levels, with broad vitro activity against tested variants. The resulted abrogation viremia all general improvement 15 survivors met primary endpoint. Thirteen endpoint at follow-up after months. Two subjects persistent carriage relapsed but successfully retreated IVIG.ConclusionsAntibodies efficiently neutralized several Treatment was associated clearance patients. Our data suggests could be novel alternative this category.

Язык: Английский

Процитировано

8
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19 DOI Creative Commons
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson

и другие.

mBio, Год журнала: 2024, Номер 15(5)

Опубликована: Апрель 11, 2024

Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. In addition, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. this context, there interest in understanding clinical benefit convalescent plasma collected from persons who been both naturally infected vaccinated against ("vax-plasma"). Thus, we report outcome 386 immunocompromised outpatients were diagnosed received contemporary COVID-19-specific therapeutics (standard-of-care group) a subgroup also concomitant treatment very titer (vax-plasma specific focus on rates. The overall rate was 2.2% (5 225 patients) vax-plasma group 6.2% (10 161 standard-of-care group, which corresponded relative reduction 65% (

Язык: Английский

Процитировано

6
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review DOI Creative Commons
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz

и другие.

Journal of Antimicrobial Chemotherapy, Год журнала: 2025, Номер unknown

Опубликована: Янв. 13, 2025

Abstract Background Persistent COVID-19 (pCOVID-19) in immunocompromised patients is characterized by unspecific symptoms and pulmonary infiltrates due to ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) replication. Treatment options remain unclear, leading different approaches, including combination therapy extended durations. The purpose of this study was assess the efficacy safety antiviral therapies for pCOVID-19 since Omicron surge. Methods We searched MEDLINE Scopus from 1 January 2022 6 August 2024 cohort studies case series on nirmatrelvir/ritonavir, remdesivir, ensitrelvir molnupiravir. Evidence certainty rated using Grading Recommendations Assessment, Development, Evaluation outcomes viral clearance, recurrence/relapse, mortality, adverse events (AEs) symptom resolution. Results Thirteen involving 127 cases were included. very low. In with at least two direct agents, clearance 79%, a 16% recurrence rate. All-cause mortality 9%, 6% while SARS-CoV-2 positive. 47 cases, AEs reported 11%. Symptom resolution ranged 3 days studies. one agent passive immunization, 89%, an 11% rate no deaths. four documented observed. monotherapy, 100%, 15% One death, unrelated SARS-CoV-2, occurred. 12 Conclusions Based low evidence, combining immunization resulted high rates few recurrences. occurred treated antivirals. Controlled are needed.

Язык: Английский

Процитировано

0
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls DOI Creative Commons
Vitor Gabriel Lopes da Silva, G. Schmitz, Kathleen E. Sullivan

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 6, 2025

Patients with Inborn Errors of Immunity (IEI) are at higher risk severe SARS-CoV-2 infection. We evaluated humoral and cellular responses to COVID-19 vaccines in Brazilian patients IEI healthy controls. Fifty-five (13-61 years) 60 controls (13-71 received inactivated (CoronaVac), non-replicating virus-vectored (ChAdOx1 nCoV-19, AstraZeneca) or monovalent mRNA (Original strain BNT162b2, Pfizer-BioNTech) bivalent (Original/Omicron BA.1, were sampled five times. Diagnoses included common variable immunodeficiency (n=25), specific antibody deficiency (n=9), ataxia-telangiectasia (n=5), X-linked agammaglobulinemia (n=4), PIK3CD-related disorders hyper-IgM syndrome combined (n=3), STAT1 gain-of-function (n=1). Humoral immunity was assessed via multiplex microarray for Spike, Nucleocapsid, RBD-Wuhan, RBD-Delta, RBD-BA.1, RBD-BA.2 RBD-BA.5 neutralizing antibodies. T-cell Spike Nucleocapsid using ELISpot. exhibited significantly lower levels RBD-neutralizing antibodies (p < 0.05). Notable differences = 0.008) IgG-Nucleocapsid 0.010) emerged over time. stronger post-booster (405 vs. 149 spot-forming cells/million PBMC; p 0.002). Both groups showed enhanced Nucleocapsid-specific time 0.017). hospitalization rates among diagnosis dropped from 33.3% zero after the first booster dose. While weaker IEI, their similar Boosters both responses. After completion vaccination protocol, none hospitalized COVID-19. Robust may play a critical role protecting mortality.

Язык: Английский

Процитировано

0
Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art” DOI

Marcial Delgado‐Fernández,

Juan Diego Ruíz-Mesa,

Almudena Rojas-González

и другие.

Enfermedades Infecciosas y Microbiología Clínica, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
New technologies in therapeutic antibody development: The next frontier for treating infectious diseases DOI
Sheila M. Keating, Brett W. Higgins

Antiviral Research, Год журнала: 2024, Номер 227, С. 105902 - 105902

Опубликована: Май 9, 2024

Язык: Английский

Процитировано

3
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review DOI Creative Commons
Paul Kinsella, Michael A. Moso, C. Orla Morrissey

и другие.

Transplant Infectious Disease, Год журнала: 2024, Номер 26(3)

Опубликована: Май 29, 2024

Abstract Antiviral agents with activity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have played a critical role in disease management; however, little is known regarding the efficacy of these medications treatment SARS‐CoV‐2 infection immunocompromised patients, particularly management persistent positivity. This narrative review discusses 2019 hosts, focus on antiviral therapies. We identified 84 cases from literature describing variety approaches, including prolonged therapy ( n = 11), combination antivirals 13), and mixed antibody treatments 60). A high proportion had an underlying haematologic malignancy 67, 80%), were receipt anti‐CD20 51, 60%). Success was reported 70 (83%) which varied according to type. Combination therapies may be effective approach for individuals positivity, those that incorporate aimed at increasing neutralizing levels. Any novel approaches taken this difficult dilemma should mindful emergence resistance.

Язык: Английский

Процитировано

3
Intravenous immunoglobulin as a potential treatment for long COVID DOI
Matthew W. McCarthy

Expert Opinion on Biological Therapy, Год журнала: 2023, Номер 23(12), С. 1211 - 1217

Опубликована: Дек. 2, 2023

Introduction On 31 July 2023, the United States Department of Health and Human Services announced formation Office Long COVID Research Practice National Institutes (NIH) opened enrollment for therapeutic arm RECOVER initiative, a prospective, randomized study to evaluate new treatment options long coronavirus disease 2019 (long COVID).

Язык: Английский

Процитировано

4
The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review DOI Open Access
Adam Al‐Hakim, Mark Kačar, Sinisa Savic

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(6), С. 1717 - 1717

Опубликована: Март 16, 2024

Common Variable Immunodeficiency (CVID) is a heterogeneous primary immunodeficiency disorder characterised by impaired antibody production, leading to recurrent infections and an increased susceptibility viral pathogens. This literature review aims provide comprehensive overview of CVID’s relationship with infections, encompassing disease pathogenesis, key presenting features, specific monogenic susceptibilities, the impact COVID-19, existing treatment options. The pathogenesis CVID involves complex immunological dysregulation, including defects in B cell development, class switching, plasma differentiation. These abnormalities contribute humoral immune response against agents, predisposing individuals broad range infections. Genetic factors play prominent role CVID, drivers CVID-like are increasingly identified through advanced genomic studies. Some causes phenotype appear cause these explored review. emergence COVID-19 pandemic highlighted patients’ heightened predisposition severe outcomes explores clinical manifestations, outcomes, potential therapeutic approaches for patients. It assesses efficacy prophylactic measures vaccination immunoglobulin replacement therapy, as well trialled therapies.

Язык: Английский

Процитировано

1